TopoTarget A/S
Symbion Science Park
3 Fruebjergvej
København
Tel: 45-39-17-83-90
Fax: 45-39-17-94-92
Website: http://www.topotarget.com/
Email: info@topotarget.com
83 articles about TopoTarget A/S
-
Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing
6/26/2018
Inthera Bioscience AG today announced that three senior Pharma and Biotech Industry members joined its management team.
-
TopoTarget A/S Release: Report Pursuant To The Danish Securities Trading Act, Section 28a
7/1/2014
-
TopoTarget A/S Release: New Articles Of Association Following Capital Increase
7/1/2014
-
BioAlliance Pharma And TopoTarget A/S Shareholders Approve Proposed Cross-Border Merger To Create Onxeo
6/30/2014
-
TopoTarget A/S Release: Notice To Convene Extraordinary General Meeting
5/27/2014
-
BioAlliance Pharma, TopoTarget A/S To Merge, Combined Entity To Be Named Onxeo
5/22/2014
-
TopoTarget A/S Announces Interim Report For The Period January 1 - March 31, 2014
5/8/2014
-
TopoTarget A/S Release: Teleconference Regarding Interim Report For The Period January 1 - March 31, 2014
5/1/2014
-
Healthcap IV Is Committed To Vote In Support Of TopoTarget A/S’s Proposed Merger With BioAlliance Pharma
4/29/2014
-
TopoTarget A/S Release: Passing On Annual General Meeting
4/25/2014
-
BioAlliance Pharma And TopoTarget A/S To Merge To Form Orphan Oncology Powerhouse
4/16/2014
-
TopoTarget A/S Release: Notice To Convene Annual General Meeting 2014
3/28/2014
-
TopoTarget A/S Confirms Receipt Of Acceptance-To-File Milestone Payment
3/27/2014
-
TopoTarget A/S Announces Financial Results For The Year Ended Dec 31, 2013
3/27/2014
-
TopoTarget A/S Release: Teleconference Regarding Annual Report 2013
3/20/2014
-
FDA Grants Acceptance To File And Priority Review For TopoTarget A/S's Beleodaq™ (Belinostat) NDA In PTCL
2/6/2014
-
TopoTarget A/S Announces Interim Report For The Period January 1 - December 31, 2013
1/30/2014
-
TopoTarget A/S Release: Teleconference Regarding Interim Report For The Period January 1 – December 31, 2013
1/23/2014
-
TopoTarget A/S Release: New Drug Application For Belinostat In Relapsed Or Refractory PTCL Submitted To The FDA In The USA
12/10/2013
-
TopoTarget A/S Release: Allowance Of Key Belinostat Patent In Europe
11/21/2013